The Administrative Core will be responsible for the overall administration of the Program. It will provide clerical support, meeting organization, data management and planning/evaluation services to the Program. Dr. Lynda Chin (PI) and Dr. Flaherty (Co-PI) will work jointly, in a collaborative effort, to oversee the Administrative Core. Both Drs. Chin and Flaherty are highly experienced in organizing and maintaining multi-institutional, multi-investigator initiatives. Dr. Chin will primarily be responsible for administration of the academic research activities, while Dr. Flaherty will primarily administrate the clinical aspects of this Program. Importantly, this core will play an active role in coordination with other centers within the TMEN network to promote synergistic and collaborative interactions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163125-02
Application #
8555327
Study Section
Special Emphasis Panel (ZCA1-SRLB-3 (O1))
Project Start
2011-09-21
Project End
2016-07-31
Budget Start
2012-09-05
Budget End
2013-07-31
Support Year
2
Fiscal Year
2012
Total Cost
$169,812
Indirect Cost
$129,232
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Xu, Jie; Sun, Heather H; Fletcher, Christopher D M et al. (2016) Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. Am J Surg Pathol 40:443-53
Pfirschke, Christina; Engblom, Camilla; Rickelt, Steffen et al. (2016) Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity 44:343-54
Smith, Michael P; Brunton, Holly; Rowling, Emily J et al. (2016) Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell 29:270-84
Peng, Weiyi; Chen, Jie Qing; Liu, Chengwen et al. (2016) Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov 6:202-16
Chen, Pei-Ling; Roh, Whijae; Reuben, Alexandre et al. (2016) Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov 6:827-37
Reardon, David A; Gokhale, Prafulla C; Klein, Sarah R et al. (2016) Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res 4:124-35
Lesokhin, Alexander M; Ansell, Stephen M; Armand, Philippe et al. (2016) Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol 34:2698-704
Ansell, Stephen M; Lesokhin, Alexander M; Borrello, Ivan et al. (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311-9
Mahoney, Kathleen M; Rennert, Paul D; Freeman, Gordon J (2015) Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14:561-84
Mahoney, Kathleen M; Sun, Heather; Liao, Xiaoyun et al. (2015) PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunol Res 3:1308-15

Showing the most recent 10 out of 29 publications